The CSL Limited (ASX: CSL) share price is edging higher on Tuesday morning.
At the time of writing, the biotherapeutics giantâs shares are up 0.5% to $306.36.
Why is the CSL share price rising?
The CSL share price is rising today after the market responded relatively positively to the release of the companyâs half year results.
For the six months ended 31 December, CSL reported a 19% increase in revenue to US$7,183.5 million and a 10% lift in net profit after tax before amortisation (NPATA) in constant currency to US$1,957 million.
This was driven partly by a five-month contribution from Vifor Pharma, strong growth in immunoglobulin and albumin sales, and record levels of plasma collections.
This allowed the CSL board to lift its interim dividend by 2.9% to US$1.07 per share.
Looking ahead, management has reaffirmed its guidance for FY 2023 NPATA in the range of approximately US$2.7 billion to US$2.8 billion at constant currency.
How does this compare to expectations?
Analysts at Goldman Sachs have had a quick look at the result and given their verdict.
While the broker described the result as “untidy” it acknowledges that it appears “in-line to slightly ahead.”
This appears to explain why the CSL share price is rising this morning. It commented:
Juggling various profit lines, we expect the market to focus on a combination of: 1) statutory NPAT (-8% YoY, but flat at constant currency), both seemingly in-line with consensus; and 2) NPATA (+2% YoY, but +10% at constant currency), which appears +3% ahead. CSL may be running slightly ahead of FY guidance on the NPATA adjustments but this is not clear, and we will await further colour on the call. In any case, FY23 guidance for NPATA of $2.7-2.8bn has been reiterated, which we also presume to mean that the prior NPAT guidance remains in effect.
The post CSL share price lifts on half-year earnings beat appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL right now?
Before you consider CSL , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
See The 5 Stocks
*Returns as of February 1 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- CSL share price on watch amid US$1.6b profit
- 5 things to watch on the ASX 200 on Tuesday
- How I’d generate a $10,000 second income from CSL shares
- 5 ASX 200 shares I would buy if I was starting from scratch: expert
- Brokers name 3 ASX shares to buy now
Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/ftH86T9
Leave a Reply